Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.64 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.64 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.64 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.47 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.43 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KDM6B | O15054 | 1/20 | 0.43 |
| ▸ | KDM5C | P41229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4042291 | 1.00 | TSHR (0.64) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Fumaric Acid SCHEMBL4337403 | 1.00 | TSHR (0.64) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Maleic Acid SCHEMBL27498394 | 1.00 | TSHR (0.64) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Fumaric Acid SCHEMBL4337405 | 1.00 | TSHR (0.64) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Fumaric Acid SCHEMBL4042292 | 1.00 | TSHR (0.64) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Fumaric Acid SCHEMBL2390060 | 1.00 | TSHR (0.64) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Maleic Acid SCHEMBL725507 | 1.00 | TSHR (0.64) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Fumaric Acid SCHEMBL10458273 | 0.97 | TSHR (0.60) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Maleic Acid SCHEMBL29222106 | 0.97 | TSHR (0.60) | TSHRLMNAEGLN1TP53ALKBH5 | |
| Maleic Acid SCHEMBL27558801 | 0.94 | TSHR (0.56) | TSHRLMNAEGLN1TP53ALKBH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108641970-B | Aspergillus oryzae capable of reducing accumulation of byproducts in malic acid synthesis process and application thereof | 江南大学 | 2020-09-04 | — | — | CN | claimed |
| CN-106190936-B | Bacterium and construction method and application thereof | 上海交通大学 | 2020-07-10 | — | — | CN | claimed |
| CN-106190901-B | Bacterium and obtaining method and application thereof | 上海交通大学 | 2020-06-26 | — | — | CN | claimed |
| CN-108641970-A | It is a kind of to reduce the aspergillus oryzae of byproducts build-up and its application in malic acid building-up process | 江南大学 | 2018-10-12 | — | — | CN | claimed |
| EP-2403520-B1 | INSULIN FORMULATIONS FOR RAPID UPTAKE | LILLY CO ELI (US) | 2018-04-25 | — | — | EP | claimed |
| EP-4350323-A2 | SYSTEM FOR PREPARING AN OUTPUT SAMPLE COMPRISING A DEFINED CONCENTRATION OF AN INFECTIOUS AGENT FOR DOWNSTREAM TESTING | Avails Medical, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-3968021-B1 | SYSTEM FOR PREPARING AN OUTPUT SAMPLE COMPRISING A DEFINED CONCENTRATION OF AN INFECTIOUS AGENT FOR DOWNSTREAM TESTING | AVAILS MED INC (US) | 2024-04-03 | — | — | EP | disclosed |
| US-20240091375-A1 | AN ANTIBODY FRAGMENT BASED ANTIMICROBIAL CONJUGATE SELECTIVELY TARGETING PSEUDOMONAS | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2024-03-21 | — | — | US | disclosed |
| US-20230405588-A1 | APPARATUS, SYSTEMS, AND METHODS FOR PREPARING AN OUTPUT SAMPLE WITH AERATION | AVAILS MEDICAL, INC. (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230250463-A1 | APPARATUS, SYSTEMS, AND METHODS FOR DETERMINING THE CONCENTRATION OF MICROORGANISMS AND THE SUSCEPTIBILITY OF MICROORGANISMS TO ANTI-INFECTIVES BASED ON REDOX REACTIONS | AVAILS MEDICAL, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-11667656-B2 | Crystalline forms of Tenofovir alafenamide | APOTEX INC. (CA) | 2023-06-06 | — | — | US | disclosed |
| US-11655494-B2 | Apparatus, systems, and methods for determining the concentration of microorganisms and the susceptibility of microorganisms to anti-infectives based on redox reactions | AVAILS MEDICAL, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| EP-0988301-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998056788-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 1998-12-17 | — | — | WO | disclosed |
| US-5112834-A | Antisecretory and antiulcer | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1992-05-12 | — | — | US | disclosed |
| WO-1985002116-A1 | MEDIUM FOR STORING BLOOD PLATELETS | THOMAS JEFFERSON UNIVERSITY (US) | 1985-05-23 | — | — | WO | disclosed |
| US-4145557-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS | ELI LILLY AND COMPANY (US) | 1979-03-20 | — | — | US | disclosed |
| US-4062895-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC | ELI LILLY AND COMPANY (US) | 1977-12-13 | — | — | US | disclosed |
| US-4001322-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC | ELI LILLY AND COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
| US-3972934-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC | ELI LILLY AND COMPANY (US) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667656-B2 | Crystalline forms of Tenofovir alafenamide | SAMHD1, HPRT1, HAVCR2 | TSHR 3119/4885LMNA 1450/4885EGLN1 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.